We read with great interest the article by JF Martín-Sánchez [1] commenting on our article "Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure" [2]. In his editorial, FJ Martín-Sánchez highlights the need to consider two others specific issues related to comorbidity in heart failure (HF), such as polypharmacy and frailty, to improve outcomes in HF patients with comorbidity. We strongly agree on what is reported about these two issues.
